Abstract:

 Objective  To observe the efficacies and safety of combined use of moxifloxacin in drug-resistant pulmonary tuberculosis. Methods  Sixty-two patients with drug-resistant pulmonary tuberculosis were randomly divided into treatment group and control group. The treatment group received additional moxifloxacin and the control group were given extra levofloxacin on the conventional amikacin, p-aminosalicylic acid, protionamide and cycloserine basis. The treatment duration lasted for 21 months, including injection for 6 months and oral use of the drug in 21 months. The entire treatment was carried out under surveillance of the providers during the hospital stay or follow up care. Results  By the end of injection treatment, negative conversion rate by sputum smear examination and sputum culturing was 78.1% for the treatment group and 46.7% for the controls, compared to 93.7% and 83.3% during the period of oral administration. X-ray imaging revealed that lesion absorption was excellent for 58% of the treatment group and 53% for the controls, and effective absorption rate were 90.1% and 80.0%, respectively. Conclusion  Combined moxifloxacin with amikacin, p-aminosalicylic acid, protionamide and  cycloserine can be effective and safe for drug-resistant pulmonary tuberculosis, with better negative conversion rate and lesion absorption.
【Key words】【Abstract】 Objective  To observe the efficacies and safety of combined use of moxifloxacin in drug-resistant pulmonary tuberculosis. Methods  Sixty-two patients with drug-resistant pulmonary tuberculosis were randomly divided into treatment group and control group. The treatment group received additional moxifloxacin and the control group were given extra levofloxacin on the conventional amikacin, p-aminosalicylic acid, protionamide and cycloserine basis. The treatment duration lasted for 21 months, including injection for 6 months and oral use of the drug in 21 months. The entire treatment was carried out under surveillance of the providers during the hospital stay or follow up care. Results  By the end of injection treatment, negative conversion rate by sputum smear examination and sputum culturing was 78.1% for the treatment group and 46.7% for the controls, compared to 93.7% and 83.3% during the period of oral administration. X-ray imaging revealed that lesion absorption was excellent for 58% of the treatment group and 53% for the controls, and effective absorption rate were 90.1% and 80.0%, respectively. Conclusion  Combined moxifloxacin with amikacin, p-aminosalicylic acid, protionamide and  cycloserine can be effective and safe for drug-resistant pulmonary tuberculosis, with better negative conversion rate and lesion absorption.

Key words: Pulmonary tuberculosis, Moxifloxacin, Amikacin, p-aminosalicylic acid, Protionamide, Cycloserine, Drug resistance